

© . . . , . . . , 2014.

« - L »

. . . , . . . 2 (. . . - . . .),
« . . . » , . . . , 57.

**ANALYSIS OF THE EFFECTIVENESS OF TREATMENT OF MICROPROLACTINOMA HYPOPHYSIS IN
WOMEN WITH REGARD TO FRACTIONATION OF PROLACTIN AND CORRECTION LUTEAL
INSUFFICIENCY ON THE PRINCIPLE OF «THREE-L»**

A.A. Trushkevich, A.A. Stepur

SUMMARY

Prolactinised tumors of hypophysis occupy the third place among of tumors of the nervous system and up to 17% of brain tumors. Prolactinoma is the most common of endocrine active tumor of hypophysis, which accounted for 30% of all adenomas. The demonstrating sign of hypophysis prolactinomas is an increasing level of prolactin. The retrospective analysis of effectiveness of conservative treatment of hypophysis microprolactinomas was conducted in women of early reproductive age taking into account molecular polymorphism of prolactin and by the correction of insufficiency of luteal phase according to the principle of «three-L». The research involved 50 patients aged 18 - 26 years who were divided into two groups: the main group and the control group.

The aim of investigation was to determine the qualitative and quantitative composition of prolactin, especially the level of «little»-fraction in patients with hypophysis microadenomas, to establish the relationship of clinical manifestations and hormonal data survey, to justify a differentiated approach to the treatment of organic disease of hypophysis.

« -L »

. . . , . . .
17% , 30% -
, . . . « -L ».
50
18.-26 , -
40% , 4

: , , .
, -), 7,3% 18% (
, - 25 %) [. . . , 2004; -
P.A., 2004; . . . , 2005; . . .
() 13,9 100 [1, . . . , 2005].
- ,
-
(- (100 755 1 . -

2014, 17, 2 (66) -

) [. . ., 2002; . . ., 2004].

(1-2%),

: 75% - 18

30 [4, 7, 9, 10].

(). -

50

268,6 ±24,88

6, 12, 18, 24 30 36

[3,5,8].

- Cobas 6000 (e 601)
RosheDiagnostics ().

« » .
IMMULITE2000(- Siemens Health care
Diagnostics Inc,).

25 %
(/PEG ; PEG 6000,
MerckSchuchardOHG Germany).
50 PEG

18 - 26 ,
: .

1 1 ,
1 25
(
22,8±0,98)
1226±288 / ,

3000 . 15 .
()
IMMULITE
2000.

« - » W

«Medstat».

(,),
 (. 1).

1 1

(±m)

| | 1 (n=25) | 1 (n=25) | (n=50) |
|---------|-----------------|------------------|-------------|
| 3.00, / | 387±32,69* | 501,2±48,5 | 567,6±27,36 |
| 6.00, / | 1001,8±61,51*** | 1019,8±160,79*** | 285,4±54,97 |
| , / | 5,9±0,99 | 5,2±1,01 | 3,9±0,58 |
| , / | 5,3±0,50 | 5,1±1,01 | 4,9±0,50 |
| , / | 1,9±0,10* | 2,3±0,18 | 2,6±0,16 |
| 4 ., / | 12,6±0,32 | 12,0±0,59 | 12,8±0,41 |
| 3, / | 2,8±0,14* | 2,9±0,22* | 3,7±0,07 |
| , / | 596,8±22,42* | 634,8±60,02** | 390,9±29,42 |
| 17- , / | 2,0±0,12* | 2,1±0,17* | 1,5±0,05 |
| - , / | 2,3±0,19 | 2,1±0,27 | 2,4±0,22 |

: *<0,05;**<0,01; ***<0,001.

1 1 4,20±1,37 3,46±1,49
 . 6 12

-1 6-12 (±m)

| | 3 . | 6 . | 12 . | n=50 |
|--|---------------|--------------|-------------|-----------|
| | 100,0±2,39*** | 49,2±1,49** | 15,3±1,15* | 24,0±2,4 |
| | 67,8±1,68*** | 10,2±1,10 | - | 10,0±1,11 |
| | 71,2±1,71*** | 10,2±1,10** | 6,8±1,07* | 4,0±0,4 |
| | 66,1±1,66*** | 38,9±1,38** | 3,4±0,3*** | 14,0±1,4 |
| | 59,3±1,59*** | 11,9±1,12 | 1,7±0,2*** | 14,0±1,4 |
| | 59,3±1,59*** | 18,6±1,19* | 5,1±0,5** | 10,0±1,0 |
| | 38,9±1,39*** | 3,4±0,3* | - | - |
| | 52,5±1,53*** | 13,6±1,13** | 1,7±0,1** | 4,0±0,4 |
| | 67,8±1,68*** | 42,4±1,42*** | 22,0±1,22** | - |
| | 100,0±2,86*** | 50,9±1,56** | 6,8±0,7*** | 34,0±3,4 |
| | 47,5±1,48*** | 3,4±0,3 | - | 4,0±1,04 |
| | 32,2±1,32* | 15,3±1,15** | 10,2±1,10** | 24,0±2,4 |

: *<0,05;**<0,01; ***<0,001.

6

-1

(.2).

-2 6 12

(.3).

3

-2

6-12 (±m)

| | 3 | 6 | 12 | (n=50) |
|--|---------------|--------------|-------------|----------|
| | 100,0±2,00*** | 96,4±1,96*** | 46,4±1,46** | 24,0±2,4 |
| | 57,1±1,57*** | 7,1±0,7* | 3,6±0,4** | 10,0±1,0 |
| | 71,4±1,71*** | 42,9±1,42*** | 3,6±0,4 | 4,0±0,4 |
| | 78,5±1,79 | 71,4±1,71 | 14,3±1,14 | 14,0±1,4 |
| | 64,3±1,64*** | 25,0±1,25** | 7,1±0,7** | 14,0±1,4 |
| | 42,9±1,43*** | 17,9±1,17* | - | 10,0±1,0 |
| | 32,1±1,32*** | - | - | - |
| | 32,1±1,32*** | 17,9±1,17** | - | 4,0±0,4 |
| | 57,1±1,57*** | 46,4±1,46*** | 21,4±1,21** | - |
| | 100,0±2,00*** | 92,9±1,93*** | 25,0±1,25* | 34,0±3,4 |
| | 32,1±1,32*** | 3,6±0,4 | - | 4,0±0,4 |
| | 46,4±1,46** | 28,6±1,28 | 17,9±1,18* | 24,0±2,4 |

:

: *<0,05; **<0,01; ***<0,001.

4

6

(±m)

| | 1 (n=25) | 1 (n=25) | (n=50) |
|--|--------------|--------------|----------|
| | 49,2±1,49** | 96,4±1,96*** | 24,0±2,4 |
| | 10,2±1,10 | 7,1±1,07* | 10,0±1,0 |
| | 10,2±1,1** | 42,9±1,42*** | 4,0±0,4 |
| | 38,9±1,38** | 71,4±1,71*** | 14,0±1,4 |
| | 11,9±1,12 | 25,0±1,25** | 14,0±1,4 |
| | 18,6±1,19* | 17,9±1,17* | 10,0±1,0 |
| | 3,4±0,3** | - | - |
| | 13,6±1,13** | 17,9±1,17** | 4,0±0,4 |
| | 42,4±1,42*** | 46,4±1,46*** | - |
| | 50,9±1,56* | 92,9±1,93** | 34,0±1,4 |
| | 3,4±0,3 | 3,6±0,4 | 4,0±0,4 |
| | 15,3±1,15** | 28,6±1,28 | 24,0±2,4 |

:

: *<0,05; **<0,01; ***<0,001.

1 1 -1 12 -
 - , 70,7 %.
 -1 « -L» (.4). -2 ()
 12 - 58,7 %
 (.5). 52,0 %
 5

| | | |
|----|------------|-----------|
| | | 12 |
| -1 | 4,20±1,68* | 1,23±1,54 |
| -2 | 3,16±1,37* | 1,43±1,48 |

: * <0,05 12
 - 6. .46 - 48.
 - 2. . . .
 - //
 - .2013. 59, 1. 62-69.
 « -L» 3. . . , . . .
 - ,
 - . . : - ,2007. .29-69.
 , () 4. . . : ,
 - : ,2007.14 .
 5. . . , . . .
 //
 1. 1 1 - 2012. 2. .48 - 59.
 - 6. . . , . . .
 - a-
 -1 « -L». x xp
 2. 12 // x a p .2011. 1.
 . 52,0% - .86 - 88.
 , -1 - ,2010. 240 .
 70,7 % - 8. . . , . . .
 () -2 58,7 %, . : ,2009. 84 .
 9. Antonio Ciccarelli, Adrian F. Daly, Albert Beckers. The Epidemiology of Prolactinomas // Pituitary. 2010. Vol. 8. 1. .3 - 6.
 1. . . , 10.K. Thapar, K. Kovacs, B.W. Scheithauer, R.V. Lloyd, Diagnosis and Management of Pituitary Tumors, - Humana press, Totowa, New Jersey, 2001. .225-246.
 // 2009. . 55,